Structure via PubChem · Public domain (PubChem)
fluvoxamine
Sign in to saveAlso known as Luvox®, U-23000, Fluvoxaminum, Fluvoxamina
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), but is also used to treat anxiety disorders such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 443824781
- Drug.image
- Fluvoxamine.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- FLUVOXAMINE_3d-ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 276
- Drug.pronounce
- UK: US:
- Drug.tradename
- Luvox, others
- Drug.MedlinePlus
- a695004
- Drug.DailyMedID
- Fluvoxamine
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.class
- Selective serotonin reuptake inhibitor (SSRI)
- Drug.ATC_prefix
- N06
- Drug.ATC_suffix
- AB08
- Drug.legal_AU
- S4
via Wikipedia infobox
Chemical data
- Formula
- C15H21F3N2O2
- Molecular weight
- 318.33 g/mol
- IUPAC name
- 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine
- SMILES
- COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F
- InChIKey
- CJOFXWAVKWHTFT-XSFVSMFZSA-N
- XLogP
- 2.6
- Polar surface area
- 56.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
3,573 papers- Fluvoxamine for symptomatic outpatients with COVID-19.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
- [Fluvoxamine in the treatment of anxiety-depressive spectrum disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024
- Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials.Journal of clinical psychopharmacology · 2020
- Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.Drugs · 2021
- Lack of Benefit of Fluvoxamine for COVID-19.JAMA · 2023
via PubMed
~17 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Adverse effects
- Common
- Uncommon
- Rare
- Unknown frequency
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Research directions
- Environment
- References
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443824781 | image = Fluvoxamine.svg | image_class = skin-invert-image | width = | alt = | caption = | image2 = FLUVOXAMINE_3d-ball-and-stick.png | image_class2 = bg-transparent | width2 = 276 | alt2 = | pronounce = UK: US: | tradename = Luvox, others | Drugs.com = | MedlinePlus = a695004 | DailyMedID = Fluvoxamine | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Selective serotonin reuptake inhibitor (SSRI) | ATC_prefix = N06 | ATC_suffix = AB08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = C1 | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status =
| bioavailability = 53% (90% confidence interval: 44–62%) | protein_bound = 77–80% | metabolism = Liver (primarily O-demethylation)Major: CYP2D6 or CYP1A2Minor: CYP3A4, CYP2C19, and/or CYP1A2 | metabolites = | onset = | elimination_half-life = 12–13 hours (single dose), 22 hours (repeated dosing) | duration_of_action = | excretion = Kidney (98%; 94% as metabolites, 4% as unchanged drug)
Excerpted from Wikipedia’s “fluvoxamine” article, available under the CC BY-SA 4.0 licence.